Implant removal tool
Latest INTARCIA THERAPEUTICS, INC. Patents:
- Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
- Methods comprising continuous administration of exenatide and co-administration of a drug
- Suspension formulation comprising an insulinotropic peptide
- Glucagon-receptor selective polypeptides and methods of use thereof
- Implant removal tool and assembly
Description
Claims
The ornamental design for an implant removal tool, as shown and described.
Referenced Cited
U.S. Patent Documents
Foreign Patent Documents
Other references
1655158 | January 1928 | Muir |
2110208 | March 1938 | Eggert |
2168437 | August 1939 | Buercklin |
2531724 | November 1950 | Cevasco |
D179537 | January 1957 | Floyd et al. |
3025991 | March 1962 | Gillon |
3122162 | February 1964 | Sands |
3463157 | August 1969 | Hunt |
3523906 | August 1970 | Vrancken et al. |
3538916 | November 1970 | Groff et al. |
3620216 | November 1971 | Szymanski |
3625214 | December 1971 | Higuchi |
3632768 | January 1972 | Bergy et al. |
3669104 | June 1972 | Wyatt et al. |
3691090 | September 1972 | Kitajima et al. |
D226915 | May 1973 | Huggins |
3732865 | May 1973 | Higuchi et al. |
3737337 | June 1973 | Schnoring et al. |
3766915 | October 1973 | Rychlik |
3773919 | November 1973 | Boswell et al. |
3797492 | March 1974 | Place |
3869549 | March 1975 | Geller |
3891570 | June 1975 | Fukushima et al. |
D236035 | July 1975 | Ciencewicki |
3960757 | June 1, 1976 | Morishita et al. |
3987790 | October 26, 1976 | Eckenhoff et al. |
3995631 | December 7, 1976 | Higuchi et al. |
3995632 | December 7, 1976 | Nakano et al. |
4008719 | February 22, 1977 | Theeuwes et al. |
4034756 | July 12, 1977 | Higuchi et al. |
4078060 | March 7, 1978 | Benson et al. |
4105030 | August 8, 1978 | Kercso |
4111201 | September 5, 1978 | Theeuwes |
4111202 | September 5, 1978 | Theeuwes |
4111203 | September 5, 1978 | Theeuwes |
4203439 | May 20, 1980 | Theeuwes |
4211771 | July 8, 1980 | Witkowski et al. |
4221862 | September 9, 1980 | Naito et al. |
4223674 | September 23, 1980 | Fluent et al. |
4243030 | January 6, 1981 | Lynch et al. |
D258837 | April 7, 1981 | Spranger et al. |
D259458 | June 9, 1981 | Fuller et al. |
4305927 | December 15, 1981 | Theeuwes et al. |
4310516 | January 12, 1982 | Chang et al. |
4340054 | July 20, 1982 | Michaels |
4350271 | September 21, 1982 | Eckenhoff |
4373527 | February 15, 1983 | Fischell |
4376118 | March 8, 1983 | Daher et al. |
4384975 | May 24, 1983 | Fong |
4389330 | June 21, 1983 | Tice et al. |
D271990 | December 27, 1983 | Lyne |
4439196 | March 27, 1984 | Higuchi |
4444498 | April 24, 1984 | Heinemann |
4451253 | May 29, 1984 | Harman |
4455143 | June 19, 1984 | Theeuwes et al. |
4455145 | June 19, 1984 | Theeuwes |
4474572 | October 2, 1984 | McNaughton et al. |
4530840 | July 23, 1985 | Tice et al. |
4552561 | November 12, 1985 | Eckenhoff et al. |
4588614 | May 13, 1986 | Lauchenauer |
4594108 | June 10, 1986 | Greminger, Jr. et al. |
4597753 | July 1, 1986 | Turley |
4609374 | September 2, 1986 | Ayer |
4639244 | January 27, 1987 | Rizk et al. |
4655462 | April 7, 1987 | Balsells |
4657533 | April 14, 1987 | Oscarsson |
4673405 | June 16, 1987 | Guittard et al. |
4675184 | June 23, 1987 | Hasegawa et al. |
4695623 | September 22, 1987 | Stabinsky |
4727138 | February 23, 1988 | Goeddel et al. |
4734284 | March 29, 1988 | Terada et al. |
4737437 | April 12, 1988 | Gutsell, Jr. et al. |
4743449 | May 10, 1988 | Yoshida et al. |
4753651 | June 28, 1988 | Eckenhoff |
4762791 | August 9, 1988 | Goeddel et al. |
4765989 | August 23, 1988 | Wong et al. |
4783337 | November 8, 1988 | Wong et al. |
4818517 | April 4, 1989 | Kwee et al. |
4820267 | April 11, 1989 | Harman |
4820638 | April 11, 1989 | Swetly et al. |
4826144 | May 2, 1989 | Balsells |
4830344 | May 16, 1989 | Balsells |
4834708 | May 30, 1989 | Pillari |
4845196 | July 4, 1989 | Cowling |
4847079 | July 11, 1989 | Kwan |
4851228 | July 25, 1989 | Zentner et al. |
4840896 | June 20, 1989 | Reddy et al. |
4865845 | September 12, 1989 | Eckenhoff et al. |
4871094 | October 3, 1989 | Gall et al. |
4873080 | October 10, 1989 | Brickl et al. |
4874388 | October 17, 1989 | Wong et al. |
4876781 | October 31, 1989 | Balsells |
4882166 | November 21, 1989 | Graham et al. |
4885166 | December 5, 1989 | Meyer et al. |
4886668 | December 12, 1989 | Haslam et al. |
4892778 | January 9, 1990 | Theeuwes et al. |
4893795 | January 16, 1990 | Balsells |
4897471 | January 30, 1990 | Stabinsky |
4907788 | March 13, 1990 | Balsells |
4915366 | April 10, 1990 | Balsells |
4915949 | April 10, 1990 | Wong et al. |
4915954 | April 10, 1990 | Ayer et al. |
4917887 | April 17, 1990 | Hauptmann et al. |
4917895 | April 17, 1990 | Lee et al. |
4923805 | May 8, 1990 | Reddy et al. |
4927687 | May 22, 1990 | Nuwayser |
4929554 | May 29, 1990 | Goeddel et al. |
4931285 | June 5, 1990 | Edgren et al. |
4934666 | June 19, 1990 | Balsells |
4940465 | July 10, 1990 | Theeuwes et al. |
4940588 | July 10, 1990 | Sparks et al. |
4952402 | August 28, 1990 | Sparks et al. |
4957119 | September 18, 1990 | de Nijs |
4961253 | October 9, 1990 | Balsells |
4964204 | October 23, 1990 | Balsells |
4969884 | November 13, 1990 | Yum |
4974821 | December 4, 1990 | Balsells |
4976966 | December 11, 1990 | Theeuwes et al. |
4994028 | February 19, 1991 | Leonard et al. |
5004689 | April 2, 1991 | Fiers et al. |
5006346 | April 9, 1991 | Theeuwes et al. |
5019382 | May 28, 1991 | Cummins, Jr. |
5019400 | May 28, 1991 | Gombotz et al. |
5023088 | June 11, 1991 | Wong et al. |
5024842 | June 18, 1991 | Edgren et al. |
5030216 | July 9, 1991 | Theeuwes et al. |
5034229 | July 23, 1991 | Magruder et al. |
5053014 | October 1, 1991 | Van Heugten |
5057318 | October 15, 1991 | Magruder et al. |
5059423 | October 22, 1991 | Magruder et al. |
5066436 | November 19, 1991 | Komen et al. |
5071642 | December 10, 1991 | Lahr et al. |
5072070 | December 10, 1991 | Balsells |
5079388 | January 7, 1992 | Balsells |
5090962 | February 25, 1992 | Landry et al. |
5091188 | February 25, 1992 | Haynes |
5108078 | April 28, 1992 | Balsells |
5110596 | May 5, 1992 | Magruder et al. |
5112614 | May 12, 1992 | Magruder et al. |
5113938 | May 19, 1992 | Clayton |
5117066 | May 26, 1992 | Balsells |
D326718 | June 2, 1992 | Maxwell et al. |
5118666 | June 2, 1992 | Habener |
5120306 | June 9, 1992 | Gosselin |
5120712 | June 9, 1992 | Habener |
5120832 | June 9, 1992 | Goeddel et al. |
5122128 | June 16, 1992 | Cardinal et al. |
5122377 | June 16, 1992 | Miller |
5126142 | June 30, 1992 | Ayer et al. |
5126147 | June 30, 1992 | Silvestri et al. |
5134244 | July 28, 1992 | Balsells |
5137727 | August 11, 1992 | Eckenhoff |
D329278 | September 8, 1992 | Gallup |
5147295 | September 15, 1992 | Stewart |
5151093 | September 29, 1992 | Theeuwes et al. |
5160122 | November 3, 1992 | Balsells |
5160743 | November 3, 1992 | Edgren et al. |
5161806 | November 10, 1992 | Balsells |
5180591 | January 19, 1993 | Margruder et al. |
5190765 | March 2, 1993 | Jao et al. |
5192273 | March 9, 1993 | Bierman |
5203849 | April 20, 1993 | Balsells |
5204108 | April 20, 1993 | Illum |
5207752 | May 4, 1993 | Sorensen et al. |
5209746 | May 11, 1993 | Balaban et al. |
5213809 | May 25, 1993 | Wright et al. |
5213810 | May 25, 1993 | Steber |
5219572 | June 15, 1993 | Sivaramakrishnan |
5221278 | June 22, 1993 | Linkwitz et al. |
5223265 | June 29, 1993 | Wong |
5225205 | July 6, 1993 | Orsolini |
5231176 | July 27, 1993 | Goeddel et al. |
5234424 | August 10, 1993 | Yum et al. |
5234692 | August 10, 1993 | Magruder et al. |
5234693 | August 10, 1993 | Magruder et al. |
5234695 | August 10, 1993 | Hobbs et al. |
5250026 | October 5, 1993 | Ehrlich et al. |
5252338 | October 12, 1993 | Jao et al. |
5260069 | November 9, 1993 | Chen |
D342855 | January 4, 1994 | Butler, II |
5276926 | January 11, 1994 | Lopez |
5278151 | January 11, 1994 | Korb et al. |
5279544 | January 18, 1994 | Gross et al. |
5279554 | January 18, 1994 | Turley |
5279555 | January 18, 1994 | Lifshey |
5279608 | January 18, 1994 | Cherif Cheikh |
5284655 | February 8, 1994 | Bogdansky et al. |
5288501 | February 22, 1994 | Numberg et al. |
5288502 | February 22, 1994 | Mcginity et al. |
5290271 | March 1, 1994 | Jernberg |
5300079 | April 5, 1994 | Niezink et al. |
5300302 | April 5, 1994 | Tachon et al. |
5308348 | May 3, 1994 | Balaban et al. |
5312335 | May 17, 1994 | McKinnon et al. |
5312389 | May 17, 1994 | Theeuwes et al. |
5312390 | May 17, 1994 | Wong |
5318558 | June 7, 1994 | Linkwitz et al. |
5318780 | June 7, 1994 | Viegas et al. |
5320616 | June 14, 1994 | Magndu et al. |
5324280 | June 28, 1994 | Wong et al. |
5336057 | August 9, 1994 | Fukuda et al. |
5336505 | August 9, 1994 | Ng et al. |
5348544 | September 20, 1994 | Sweeney et al. |
5352662 | October 4, 1994 | Brooks et al. |
5368588 | November 29, 1994 | Bettinger |
5368863 | November 29, 1994 | Eckenhoff et al. |
5371089 | December 6, 1994 | Rattan |
5374620 | December 20, 1994 | Clark et al. |
5385738 | January 31, 1995 | Yamahira et al. |
5385887 | January 31, 1995 | Yim et al. |
5395319 | March 7, 1995 | Hirsch et al. |
5407609 | April 18, 1995 | Tice et al. |
D358644 | May 23, 1995 | Park |
5411951 | May 2, 1995 | Mitchell |
5413572 | May 9, 1995 | Wong et al. |
5413672 | May 9, 1995 | Hirotsuji et al. |
5424286 | June 13, 1995 | Eng |
5428024 | June 27, 1995 | Chu et al. |
5429602 | July 4, 1995 | Hauser |
5439688 | August 8, 1995 | Orsolini et al. |
5443459 | August 22, 1995 | Wong et al. |
5445829 | August 29, 1995 | Paradissis et al. |
5456679 | October 10, 1995 | Balaban et al. |
5458888 | October 17, 1995 | Chen |
5464929 | November 7, 1995 | Bezwada et al. |
5472708 | December 5, 1995 | Chen |
5478564 | December 26, 1995 | Wantier et al. |
5484403 | January 16, 1996 | Yoakum et al. |
5486365 | January 23, 1996 | Takado et al. |
5498255 | March 12, 1996 | Wong et al. |
5511355 | April 30, 1996 | Dingler |
5512293 | April 30, 1996 | Landrau et al. |
5512549 | April 30, 1996 | Chen et al. |
5514110 | May 7, 1996 | Teh |
5529914 | June 25, 1996 | Hubbell et al. |
5531736 | July 2, 1996 | Wong et al. |
5540665 | July 30, 1996 | Mercado et al. |
5540912 | July 30, 1996 | Roorda et al. |
5541172 | July 30, 1996 | Labrie et al. |
5542682 | August 6, 1996 | Goldstein et al. |
5543156 | August 6, 1996 | Roorda et al. |
5545618 | August 13, 1996 | Buckley et al. |
5556642 | September 17, 1996 | Kobayashi et al. |
5557318 | September 17, 1996 | Gabriel |
5558637 | September 24, 1996 | Allonen et al. |
5569289 | October 29, 1996 | Yoon |
5571525 | November 5, 1996 | Roorda et al. |
5574008 | November 12, 1996 | Johnson et al. |
5574137 | November 12, 1996 | Gray et al. |
5580578 | December 3, 1996 | Oshlack et al. |
5589167 | December 31, 1996 | Cleland et al. |
5595751 | January 21, 1997 | Bezwada |
5595759 | January 21, 1997 | Wright et al. |
5597579 | January 28, 1997 | Bezwada et al. |
5602010 | February 11, 1997 | Hauptmann et al. |
5605688 | February 25, 1997 | Himmler et al. |
5607687 | March 4, 1997 | Bezwada et al. |
5609885 | March 11, 1997 | Rivera et al. |
5613954 | March 25, 1997 | Nelson et al. |
5614221 | March 25, 1997 | Fjellstrom |
5614492 | March 25, 1997 | Habener |
5656299 | August 12, 1997 | Kino et al. |
5618552 | April 8, 1997 | Bezwada et al. |
5620698 | April 15, 1997 | Bezwada et al. |
5620705 | April 15, 1997 | Dong et al. |
5630796 | May 20, 1997 | Bellhouse et al. |
5633011 | May 27, 1997 | Dong et al. |
5635213 | June 3, 1997 | Nystrom et al. |
5639477 | June 17, 1997 | Maruyama et al. |
5639640 | June 17, 1997 | Reddy et al. |
5645850 | July 8, 1997 | Bezwada et al. |
5648088 | July 15, 1997 | Bezwada et al. |
5650173 | July 22, 1997 | Ramstack et al. |
5654008 | August 5, 1997 | Herbert et al. |
5654010 | August 5, 1997 | Johnson et al. |
5656297 | August 12, 1997 | Bernstein et al. |
5658593 | August 19, 1997 | Orly et al. |
5660847 | August 26, 1997 | Magruder et al. |
5660858 | August 26, 1997 | Parikh et al. |
5660861 | August 26, 1997 | Jao et al. |
5667808 | September 16, 1997 | Johnson et al. |
5668170 | September 16, 1997 | Gyory |
5672549 | September 30, 1997 | Minami et al. |
5676942 | October 14, 1997 | Testa et al. |
5686097 | November 11, 1997 | Taskovich et al. |
5688801 | November 18, 1997 | Mesens et al. |
5690925 | November 25, 1997 | Gray et al. |
5690952 | November 25, 1997 | Magruder et al. |
5695463 | December 9, 1997 | Cherif-Cheikh |
5697113 | December 16, 1997 | Shatz et al. |
5697914 | December 16, 1997 | Brimhall |
5698213 | December 16, 1997 | Jamiolkowski et al. |
5700486 | December 23, 1997 | Canal et al. |
5700583 | December 23, 1997 | Jamiolkowski et al. |
5703200 | December 30, 1997 | Bezwada et al. |
5707644 | January 13, 1998 | Illum |
5711967 | January 27, 1998 | Juch |
5713847 | February 3, 1998 | Howard, III et al. |
5718922 | February 17, 1998 | Herrero-Vanrell |
5725497 | March 10, 1998 | Woodruff et al. |
5728088 | March 17, 1998 | Margruder et al. |
5728396 | March 17, 1998 | Peery et al. |
5733572 | March 31, 1998 | Unger et al. |
5736159 | April 7, 1998 | Chen et al. |
5738845 | April 14, 1998 | Imakawa |
5747058 | May 5, 1998 | Tipton et al. |
5756450 | May 26, 1998 | Hahn et al. |
5767251 | June 16, 1998 | Reddy et al. |
5770231 | June 23, 1998 | Mesens et al. |
5782396 | July 21, 1998 | Mastri et al. |
5792477 | August 11, 1998 | Rickey et al. |
5795591 | August 18, 1998 | Lee et al. |
5795779 | August 18, 1998 | McCormick et al. |
5807876 | September 15, 1998 | Armistead et al. |
5810769 | September 22, 1998 | Schlegel et al. |
5814323 | September 29, 1998 | Lyle |
D399821 | October 20, 1998 | Tyneski |
5817129 | October 6, 1998 | Labrecque et al. |
5827297 | October 27, 1998 | Boudjema |
5830501 | November 3, 1998 | Dong et al. |
5836935 | November 17, 1998 | Ashton et al. |
5843891 | December 1, 1998 | Sherman |
5844017 | December 1, 1998 | Jamiolkowski et al. |
5851451 | December 22, 1998 | Takechi et al. |
5858746 | January 12, 1999 | Hubbell et al. |
5859150 | January 12, 1999 | Jamiolkowski et al. |
5861166 | January 19, 1999 | Eckenhoff |
5871770 | February 16, 1999 | Margruder et al. |
5871778 | February 16, 1999 | Kino et al. |
5874388 | February 23, 1999 | Hsu |
5876746 | March 2, 1999 | Jona et al. |
5882676 | March 16, 1999 | Lee et al. |
D408917 | April 27, 1999 | Hacker |
5904935 | May 18, 1999 | Eckenhoff et al. |
5906599 | May 25, 1999 | Kaldany |
5906816 | May 25, 1999 | Soos et al. |
5906830 | May 25, 1999 | Farinas et al. |
5908621 | June 1, 1999 | Glue et al. |
5916598 | June 29, 1999 | Rickey et al. |
5922253 | July 13, 1999 | Herbert et al. |
5928666 | July 27, 1999 | Farinas et al. |
5932547 | August 3, 1999 | Stevenson et al. |
5938654 | August 17, 1999 | Wong et al. |
5939286 | August 17, 1999 | Johnson et al. |
5942223 | August 24, 1999 | Bazer et al. |
5942253 | August 24, 1999 | Gombotz et al. |
5945126 | August 31, 1999 | Thanoo et al. |
5948430 | September 7, 1999 | Zerbe et al. |
5951521 | September 14, 1999 | Mastrototaro et al. |
5958909 | September 28, 1999 | Habener |
D415073 | October 12, 1999 | Meehan et al. |
5962023 | October 5, 1999 | Jamiolkowski et al. |
5965168 | October 12, 1999 | Mesens et al. |
5972370 | October 26, 1999 | Eckenhoff et al. |
5972373 | October 26, 1999 | Yajima et al. |
5976109 | November 2, 1999 | Heruth |
5980945 | November 9, 1999 | Ruiz |
5981719 | November 9, 1999 | Woiszwillo et al. |
5984890 | November 16, 1999 | Gast et al. |
5985305 | November 16, 1999 | Peery et al. |
5989463 | November 23, 1999 | Tracy et al. |
5997527 | December 7, 1999 | Gumucio et al. |
5997902 | December 7, 1999 | Maruyama et al. |
6007805 | December 28, 1999 | Foster et al. |
6017545 | January 25, 2000 | Modi |
6022561 | February 8, 2000 | Carlsson et al. |
6023802 | February 15, 2000 | King |
6029361 | February 29, 2000 | Newman |
6053927 | April 25, 2000 | Hamas |
6056718 | May 2, 2000 | Funderburk et al. |
6060450 | May 9, 2000 | Soos et al. |
6069133 | May 30, 2000 | Carlo et al. |
6074377 | June 13, 2000 | Sanfilippo, II |
6074660 | June 13, 2000 | Jamiolkowski et al. |
6074673 | June 13, 2000 | Guillen |
6100346 | August 8, 2000 | Jamiolkowski et al. |
6110503 | August 29, 2000 | Rickey et al. |
D430671 | September 5, 2000 | Shute |
6113938 | September 5, 2000 | Chen et al. |
6113947 | September 5, 2000 | Cleland et al. |
6120787 | September 19, 2000 | Gustafsson et al. |
6124261 | September 26, 2000 | Stevenson et al. |
6124281 | September 26, 2000 | Lewis et al. |
6127520 | October 3, 2000 | Ueda et al. |
6129761 | October 10, 2000 | Hubbell |
6130200 | October 10, 2000 | Brodbeck et al. |
6132420 | October 17, 2000 | Dionne et al. |
6133249 | October 17, 2000 | Hills |
6133429 | October 17, 2000 | Davis et al. |
6146139 | November 14, 2000 | Harrison, III |
6147168 | November 14, 2000 | Jamiolkowski et al. |
6156331 | December 5, 2000 | Peery et al. |
6172046 | January 9, 2001 | Albrecht |
6174547 | January 16, 2001 | Dong et al. |
6177096 | January 23, 2001 | Zerbe et al. |
6183461 | February 6, 2001 | Matsuura et al. |
6187095 | February 13, 2001 | Labrecque et al. |
6190350 | February 20, 2001 | Davis |
6190700 | February 20, 2001 | Okada et al. |
6190702 | February 20, 2001 | Takada et al. |
6191102 | February 20, 2001 | DiMarchi et al. |
6204022 | March 20, 2001 | Johnson et al. |
6217893 | April 17, 2001 | Pellet et al. |
6217906 | April 17, 2001 | Gumucio et al. |
6217908 | April 17, 2001 | Mathiowitz et al. |
6218431 | April 17, 2001 | Schoen et al. |
6224894 | May 1, 2001 | Jamiolkowski et al. |
6235712 | May 22, 2001 | Stevenson et al. |
6245349 | June 12, 2001 | Yiv et al. |
6245357 | June 12, 2001 | Edgren et al. |
6248112 | June 19, 2001 | Gambale et al. |
6251435 | June 26, 2001 | Jamiolkowski et al. |
D445975 | July 31, 2001 | Stratford |
6258377 | July 10, 2001 | New et al. |
6261584 | July 17, 2001 | Peery et al. |
6268343 | July 31, 2001 | Knudsen et al. |
6270700 | August 7, 2001 | Ignatious |
6270787 | August 7, 2001 | Ayer |
6277413 | August 21, 2001 | Sankaram |
6283949 | September 4, 2001 | Roorda |
6284264 | September 4, 2001 | Zerbe et al. |
6284727 | September 4, 2001 | Kim et al. |
6287295 | September 11, 2001 | Chen et al. |
6284725 | September 4, 2001 | Coolidge et al. |
6329336 | December 11, 2001 | Bridon et al. |
6331311 | December 18, 2001 | Brodbeck et al. |
6372218 | April 16, 2002 | Cummins, Jr. |
6372256 | April 16, 2002 | Jamiolkowski et al. |
6375978 | April 23, 2002 | Kleiner et al. |
D456776 | May 7, 2002 | Lindekugel |
6395282 | May 28, 2002 | Kende et al. |
6395292 | May 28, 2002 | Peery et al. |
6402716 | June 11, 2002 | Ryoo et al. |
6403655 | June 11, 2002 | Bezwada et al. |
6419952 | July 16, 2002 | Wong et al. |
6428517 | August 6, 2002 | Hochman et al. |
6433144 | August 13, 2002 | Morris et al. |
6436091 | August 20, 2002 | Harper et al. |
6447522 | September 10, 2002 | Gambale et al. |
6451974 | September 17, 2002 | Hansen |
6458385 | October 1, 2002 | Jamiolkowski et al. |
6458387 | October 1, 2002 | Scott et al. |
6458924 | October 1, 2002 | Knudsen et al. |
6461605 | October 8, 2002 | Cutler et al. |
6464688 | October 15, 2002 | Harper et al. |
6468961 | October 22, 2002 | Brodbeck et al. |
6471688 | October 29, 2002 | Harper et al. |
6472512 | October 29, 2002 | LaFleur et al. |
6478768 | November 12, 2002 | Kneer |
6485706 | November 26, 2002 | McCoy et al. |
6495164 | December 17, 2002 | Ramstack et al. |
6506724 | January 14, 2003 | Hiles et al. |
6508808 | January 21, 2003 | Carr et al. |
6514500 | February 4, 2003 | Bridon et al. |
6514517 | February 4, 2003 | Jamilolkowski et al. |
6524305 | February 25, 2003 | Peterson et al. |
6528093 | March 4, 2003 | Kamei et al. |
6528486 | March 4, 2003 | Larsen et al. |
D472896 | April 8, 2003 | Peiker |
6541021 | April 1, 2003 | Johnson et al. |
6544239 | April 8, 2003 | Kinsey et al. |
6544252 | April 8, 2003 | Theeuwes et al. |
6547250 | April 15, 2003 | Noble et al. |
6551613 | April 22, 2003 | Dong et al. |
6569420 | May 27, 2003 | Chen et al. |
6572890 | June 3, 2003 | Faour et al. |
6579851 | June 17, 2003 | Goeke et al. |
6589157 | July 8, 2003 | Fontayne et al. |
6592508 | July 15, 2003 | Ravins et al. |
6592887 | July 15, 2003 | Zerbe et al. |
6593295 | July 15, 2003 | Bridon et al. |
6607529 | August 19, 2003 | Jones et al. |
6626863 | September 30, 2003 | Berler |
6635268 | October 21, 2003 | Peery et al. |
6645192 | November 11, 2003 | Kenison et al. |
6667061 | December 23, 2003 | Ramstack et al. |
6670368 | December 30, 2003 | Breault et al. |
6673767 | January 6, 2004 | Brodbeck et al. |
6682522 | January 27, 2004 | Carr et al. |
6703225 | March 9, 2004 | Kojima et al. |
6703359 | March 9, 2004 | Young et al. |
6706689 | March 16, 2004 | Coolidge et al. |
6709671 | March 23, 2004 | Zerbe et al. |
6720407 | April 13, 2004 | Hughes et al. |
6730328 | May 4, 2004 | Maskiwicz et al. |
6752753 | June 22, 2004 | Hoskins et al. |
D492995 | July 13, 2004 | Rue |
6767887 | July 27, 2004 | Hoffmann et al. |
6821949 | November 23, 2004 | Bridon et al. |
6833256 | December 21, 2004 | Pontzer et al. |
6835194 | December 28, 2004 | Johnson et al. |
6840931 | January 11, 2005 | Peterson et al. |
6849708 | February 1, 2005 | Habener |
6849714 | February 1, 2005 | Bridon et al. |
6858576 | February 22, 2005 | Young et al. |
6872700 | March 29, 2005 | Young et al. |
6875748 | April 5, 2005 | Manthorpe et al. |
6887470 | May 3, 2005 | Bridon et al. |
6887849 | May 3, 2005 | Bridon et al. |
6899398 | May 31, 2005 | Albayrak |
6899887 | May 31, 2005 | Ayer |
6902744 | June 7, 2005 | Kolterman et al. |
6903186 | June 7, 2005 | Dong |
6913767 | July 5, 2005 | Cleland et al. |
6923800 | August 2, 2005 | Chen et al. |
6924264 | August 2, 2005 | Prickett et al. |
6939556 | September 6, 2005 | Lautenbach |
6956026 | October 18, 2005 | Beeley et al. |
6960192 | November 1, 2005 | Flaherty et al. |
6969702 | November 29, 2005 | Bertilsson et al. |
6976981 | December 20, 2005 | Ayer |
6989366 | January 24, 2006 | Beeley et al. |
6992065 | January 31, 2006 | Okumu |
6997922 | February 14, 2006 | Theeuwes et al. |
7008439 | March 7, 2006 | Janzen et al. |
7014636 | March 21, 2006 | Gilbert |
7022674 | April 4, 2006 | DeFelippis et al. |
7041646 | May 9, 2006 | Pan et al. |
7074423 | July 11, 2006 | Fereira et al. |
7084243 | August 1, 2006 | Glaesner et al. |
7101567 | September 5, 2006 | Sano et al. |
7101843 | September 5, 2006 | Glaesner et al. |
7112335 | September 26, 2006 | Lautenbach |
7115569 | October 3, 2006 | Beeley et al. |
7138375 | November 21, 2006 | Beeley et al. |
7138486 | November 21, 2006 | Habener et al. |
7141547 | November 28, 2006 | Rosen et al. |
7144863 | December 5, 2006 | DeFelippis et al. |
7153825 | December 26, 2006 | Young et al. |
7157555 | January 2, 2007 | Beeley et al. |
7163688 | January 16, 2007 | Peery et al. |
7163697 | January 16, 2007 | Hanes et al. |
7199217 | April 3, 2007 | DiMarchi et al. |
7205409 | April 17, 2007 | Pei et al. |
7207982 | April 24, 2007 | Dionne et al. |
7214206 | May 8, 2007 | Rue et al. |
7241457 | July 10, 2007 | Chen et al. |
7258869 | August 21, 2007 | Berry et al. |
D555589 | November 20, 2007 | Hussaini et al. |
7297761 | November 20, 2007 | Beeley et al. |
7316680 | January 8, 2008 | Gilbert |
7393827 | July 1, 2008 | Nadler |
7407499 | August 5, 2008 | Trautman |
7442682 | October 28, 2008 | Kitaura et al. |
7456254 | November 25, 2008 | Wright et al. |
7459432 | December 2, 2008 | Cowley et al. |
7521423 | April 21, 2009 | Young et al. |
7563871 | July 21, 2009 | Wright et al. |
7589169 | September 15, 2009 | Bolotin |
7604647 | October 20, 2009 | Chen |
7612176 | November 3, 2009 | Wright et al. |
7632256 | December 15, 2009 | Mosier et al. |
7635463 | December 22, 2009 | Bolotin et al. |
D608447 | January 19, 2010 | Meyer |
7655254 | February 2, 2010 | Dennis et al. |
7655257 | February 2, 2010 | Peery et al. |
7666835 | February 23, 2010 | Bloom et al. |
7682356 | March 23, 2010 | Alessi et al. |
7727519 | June 1, 2010 | Moran |
7731947 | June 8, 2010 | Eliaz et al. |
7736665 | June 15, 2010 | Patel et al. |
7741269 | June 22, 2010 | Young et al. |
7766924 | August 3, 2010 | Bombard et al. |
7790140 | September 7, 2010 | Bolotin |
7825091 | November 2, 2010 | Bloom et al. |
7829109 | November 9, 2010 | Chen et al. |
7833543 | November 16, 2010 | Gibson et al. |
7879028 | February 1, 2011 | Alessi et al. |
7879794 | February 1, 2011 | Weyer et al. |
7919109 | April 5, 2011 | Berry et al. |
D638478 | May 24, 2011 | Block |
7928065 | April 19, 2011 | Young et al. |
7964183 | June 21, 2011 | Eliaz et al. |
8039432 | October 18, 2011 | Bridon et al. |
7959938 | June 14, 2011 | Rohloff et al. |
8048438 | November 1, 2011 | Berry et al. |
8052996 | November 8, 2011 | Lautenbach et al. |
8058233 | November 15, 2011 | Cowley et al. |
8101576 | January 24, 2012 | Bloom |
8114430 | February 14, 2012 | Rohloff et al. |
8114437 | February 14, 2012 | Rohloff et al. |
8158150 | April 17, 2012 | Lautenbach et al. |
8173150 | May 8, 2012 | Berry et al. |
8202836 | June 19, 2012 | Moore et al. |
8206745 | June 26, 2012 | Rohloff et al. |
8211467 | July 3, 2012 | Rohloff et al. |
8217001 | July 10, 2012 | Cowley et al. |
8231859 | July 31, 2012 | Bolotin et al. |
8251946 | August 28, 2012 | Bardy |
8257682 | September 4, 2012 | Bolotin et al. |
8257691 | September 4, 2012 | Eliaz et al. |
8262667 | September 11, 2012 | Silver |
8263545 | September 11, 2012 | Levy et al. |
8263736 | September 11, 2012 | Berry |
8268341 | September 18, 2012 | Berry |
8273365 | September 25, 2012 | Lautenbach et al. |
8273713 | September 25, 2012 | Pittner et al. |
D669589 | October 23, 2012 | Delaey |
8277776 | October 2, 2012 | Boiotin et al. |
8278267 | October 2, 2012 | Weyer et al. |
8288338 | October 16, 2012 | Young et al. |
8298561 | October 30, 2012 | Alessi et al. |
8299025 | October 30, 2012 | Alessi et al. |
8343140 | January 1, 2013 | Alessi et al. |
8367095 | February 5, 2013 | Lautenbach et al. |
8372424 | February 12, 2013 | Berry et al. |
D678889 | March 26, 2013 | Chiu |
8398967 | March 19, 2013 | Eliaz et al. |
8440226 | May 14, 2013 | Rohloff et al. |
8454552 | June 4, 2013 | Bardy |
8460694 | June 11, 2013 | Rohloff et al. |
8470353 | June 25, 2013 | Lautenbach et al. |
8556861 | October 15, 2013 | Tsals |
8722037 | May 13, 2014 | Veenstra et al. |
8747412 | June 10, 2014 | Bae et al. |
8801700 | August 12, 2014 | Alessi et al. |
8815802 | August 26, 2014 | Kalthoff et al. |
8845726 | September 30, 2014 | Tebbe |
8858621 | October 14, 2014 | Oba et al. |
8865202 | October 21, 2014 | Zerbe et al. |
8888745 | November 18, 2014 | Van Der Graaf et al. |
8926595 | January 6, 2015 | Alessi et al. |
8940316 | January 27, 2015 | Alessi et al. |
8992961 | March 31, 2015 | Berry et al. |
8992962 | March 31, 2015 | Lautenbach et al. |
9044209 | June 2, 2015 | Dayton et al. |
9078900 | July 14, 2015 | Kuzma et al. |
9095553 | August 4, 2015 | Rohloff et al. |
9241722 | January 26, 2016 | Yu |
D750764 | March 1, 2016 | DeSocio |
9332995 | May 10, 2016 | Russo et al. |
9526763 | December 27, 2016 | Rohloff et al. |
9539200 | January 10, 2017 | Lautenbach |
9572889 | February 21, 2017 | Alessi et al. |
D789539 | June 13, 2017 | Kleiner et al. |
D789540 | June 13, 2017 | Gyorgy |
9682127 | June 20, 2017 | Alessi et al. |
RE46577 | October 24, 2017 | Collins et al. |
D805199 | December 12, 2017 | Chen et al. |
D810289 | February 13, 2018 | Jutila et al. |
9889085 | February 13, 2018 | Alessi et al. |
D816843 | May 1, 2018 | Lewis |
D819820 | June 5, 2018 | Radau et al. |
10314617 | June 11, 2019 | Bratlie |
20010012511 | August 9, 2001 | Bezwada et al. |
20010021377 | September 13, 2001 | Jamiolkowski et al. |
20010021822 | September 13, 2001 | Ayer |
20010022974 | September 20, 2001 | Ayer |
20010026793 | October 4, 2001 | Jamiolkowski et al. |
20010027311 | October 4, 2001 | Chen et al. |
20010031940 | October 18, 2001 | Loos |
20010031790 | October 18, 2001 | Beisswenger |
20010036472 | November 1, 2001 | Wong et al. |
20010040326 | November 15, 2001 | Balczun |
20020001631 | January 3, 2002 | Okumu |
20020004481 | January 10, 2002 | Cleland et al. |
20020012818 | January 31, 2002 | Ruppi et al. |
20020034532 | March 21, 2002 | Brodbeck et al. |
20020037309 | March 28, 2002 | Jaworowicz et al. |
20020048600 | April 25, 2002 | Bhatt et al. |
20020077599 | June 20, 2002 | Wojcik |
20020098180 | July 25, 2002 | Lei et al. |
20020136848 | September 26, 2002 | Yoshii et al. |
20020137666 | September 26, 2002 | Beeley et al. |
20020141985 | October 3, 2002 | Pittner et al. |
20020197185 | December 26, 2002 | Jamiolkowski et al. |
20020197235 | December 26, 2002 | Moran |
20030007992 | January 9, 2003 | Gibson et al. |
20030032947 | February 13, 2003 | Harper et al. |
20030040699 | February 27, 2003 | Talling et al. |
20030044467 | March 6, 2003 | Brodbeck et al. |
20030045454 | March 6, 2003 | Okumu et al. |
20030059376 | March 27, 2003 | Libbey et al. |
20030059471 | March 27, 2003 | Compton et al. |
20030060425 | March 27, 2003 | Ahlem et al. |
20030078618 | April 24, 2003 | Fey et al. |
20030097121 | May 22, 2003 | Jolly et al. |
20030104063 | June 5, 2003 | Babcock et al. |
20030108608 | June 12, 2003 | Laridon et al. |
20030108609 | June 12, 2003 | Berry et al. |
20030113380 | June 19, 2003 | Ramstack et al. |
20030114837 | June 19, 2003 | Peterson et al. |
20030118660 | June 26, 2003 | Rickey et al. |
20030135153 | July 17, 2003 | Hagemeier |
20030138403 | July 24, 2003 | Drustrup |
20030138491 | July 24, 2003 | Tracy et al. |
20030157178 | August 21, 2003 | Chen et al. |
20030170289 | September 11, 2003 | Chen et al. |
20030180364 | September 25, 2003 | Chen et al. |
20030186858 | October 2, 2003 | Arentsen |
20030191099 | October 9, 2003 | Bohlmann et al. |
20030211974 | November 13, 2003 | Brodbeck et al. |
20030215515 | November 20, 2003 | Truong-Le et al. |
20030220617 | November 27, 2003 | Dickerson |
20030233101 | December 18, 2003 | Lubock et al. |
20040001689 | January 1, 2004 | Goldsmith et al. |
20040001889 | January 1, 2004 | Chen et al. |
20040002442 | January 1, 2004 | Pan et al. |
20040022859 | February 5, 2004 | Chen et al. |
20040024068 | February 5, 2004 | Levy et al. |
20040024069 | February 5, 2004 | Chen et al. |
20040029784 | February 12, 2004 | Hathaway |
20040039376 | February 26, 2004 | Peery et al. |
20040047888 | March 11, 2004 | Kenison et al. |
20040097906 | May 20, 2004 | Fereira et al. |
20040101557 | May 27, 2004 | Gibson et al. |
20040102762 | May 27, 2004 | Gilbert |
20040115236 | June 17, 2004 | Chan et al. |
20040142867 | July 22, 2004 | Oi et al. |
20040142902 | July 22, 2004 | Struijker-Boudier |
20040151753 | August 5, 2004 | Chen et al. |
20040157951 | August 12, 2004 | Wolf |
20040198654 | October 7, 2004 | Glaesner et al. |
20040199140 | October 7, 2004 | Rue |
20040209801 | October 21, 2004 | Brand et al. |
20040215133 | October 28, 2004 | Weber et al. |
20040224903 | November 11, 2004 | Berry et al. |
20040225113 | November 11, 2004 | LaFleur et al. |
20040243106 | December 2, 2004 | Ayer |
20040265273 | December 30, 2004 | Li et al. |
20040266683 | December 30, 2004 | Hathaway et al. |
20040266692 | December 30, 2004 | Young et al. |
20050004557 | January 6, 2005 | Russell |
20050008661 | January 13, 2005 | Fereira et al. |
20050009742 | January 13, 2005 | Bertilsson et al. |
20050010196 | January 13, 2005 | Fereira et al. |
20050010942 | January 13, 2005 | Kim et al. |
20050070883 | March 31, 2005 | Brown et al. |
20050070927 | March 31, 2005 | Feinberg |
20050079200 | April 14, 2005 | Rathenow et al. |
20050079202 | April 14, 2005 | Chen et al. |
20050095284 | May 5, 2005 | Trautman |
20050101943 | May 12, 2005 | Ayer et al. |
20050106214 | May 19, 2005 | Chen |
20050112188 | May 26, 2005 | Eliaz et al. |
20050118206 | June 2, 2005 | Luk et al. |
20050118221 | June 2, 2005 | Blakely et al. |
20050131386 | June 16, 2005 | Freeman et al. |
20050131389 | June 16, 2005 | Peterson et al. |
20050143749 | June 30, 2005 | Zalenskiet et al. |
20050175701 | August 11, 2005 | Pan et al. |
20050201980 | September 15, 2005 | Moran |
20050215475 | September 29, 2005 | Ong et al. |
20050216087 | September 29, 2005 | Zucherman et al. |
20050266087 | December 1, 2005 | Junnarkar et al. |
20050271702 | December 8, 2005 | Wright et al. |
20050276856 | December 15, 2005 | Fereira et al. |
20050281879 | December 22, 2005 | Chen et al. |
20060013879 | January 19, 2006 | Brodbeck et al. |
20060014678 | January 19, 2006 | Cowley et al. |
20060030526 | February 9, 2006 | Liu et al. |
20060069029 | March 30, 2006 | Kolterman et al. |
20060073182 | April 6, 2006 | Wong et al. |
20060084604 | April 20, 2006 | Kitaura et al. |
20060084922 | April 20, 2006 | Botha |
20060094652 | May 4, 2006 | Levy et al. |
20060094693 | May 4, 2006 | Aziz et al. |
20060106399 | May 18, 2006 | Taras et al. |
20060141040 | June 29, 2006 | Chen et al. |
20060142234 | June 29, 2006 | Chen et al. |
20060160736 | July 20, 2006 | Nadler |
20060178304 | August 10, 2006 | Juul-Mortensen et al. |
20060193918 | August 31, 2006 | Rohloff et al. |
20060216242 | September 28, 2006 | Rohloff et al. |
20060224145 | October 5, 2006 | Gills |
20060233841 | October 19, 2006 | Brodbeck et al. |
20060246138 | November 2, 2006 | Rohloff et al. |
20060251618 | November 9, 2006 | Dennis et al. |
20060263433 | November 23, 2006 | Ayer et al. |
20060264890 | November 23, 2006 | Moberg et al. |
20060280795 | December 14, 2006 | Penhasi et al. |
20060293232 | December 28, 2006 | Levy et al. |
20070027105 | February 1, 2007 | Junnarkar et al. |
20070141102 | June 21, 2007 | De Graaff et al. |
20070149011 | June 28, 2007 | Kent et al. |
20070166352 | July 19, 2007 | Wright et al. |
20070207958 | September 6, 2007 | Bridon et al. |
20070248572 | October 25, 2007 | Moran et al. |
20070281024 | December 6, 2007 | Lautenbach et al. |
20080020016 | January 24, 2008 | Li et al. |
20080038316 | February 14, 2008 | Wong et al. |
20080064636 | March 13, 2008 | Bloom et al. |
20080091176 | April 17, 2008 | Alessi et al. |
20080065090 | March 13, 2008 | Scribner et al. |
20080110515 | May 15, 2008 | Angelosanto et al. |
20080112994 | May 15, 2008 | Junnarkar et al. |
20080194985 | August 14, 2008 | Nicoson et al. |
20080200383 | August 21, 2008 | Jennings et al. |
20080207512 | August 28, 2008 | Roth et al. |
20080208194 | August 28, 2008 | Bickenbach |
20080226625 | September 18, 2008 | Berry et al. |
20080226689 | September 18, 2008 | Berry et al. |
20080260838 | October 23, 2008 | Hokenson et al. |
20080260840 | October 23, 2008 | Alessi et al. |
20080269725 | October 30, 2008 | Deem et al. |
20080312157 | December 18, 2008 | Levy et al. |
20090012463 | January 8, 2009 | Beelen et al. |
20090022727 | January 22, 2009 | Houston et al. |
20090036364 | February 5, 2009 | Levy et al. |
20090042781 | February 12, 2009 | Petersen et al. |
20090074734 | March 19, 2009 | Rottiers |
20090087408 | April 2, 2009 | Berry et al. |
20090125030 | May 14, 2009 | Tebbe et al. |
20090156474 | June 18, 2009 | Roth et al. |
20090163447 | June 25, 2009 | Maggio |
20090186817 | July 23, 2009 | Ghosh et al. |
20090202481 | August 13, 2009 | Li et al. |
20090202608 | August 13, 2009 | Alessi et al. |
20090209460 | August 20, 2009 | Young et al. |
20090210019 | August 20, 2009 | Kim et al. |
20090215694 | August 27, 2009 | Kolterman et al. |
20090234392 | September 17, 2009 | Dziedzic et al. |
20090247463 | October 1, 2009 | Wright et al. |
20090254143 | October 8, 2009 | Tweden et al. |
20090286723 | November 19, 2009 | Levy et al. |
20090312246 | December 17, 2009 | Baron et al. |
20100092566 | April 15, 2010 | Alessi et al. |
20100094252 | April 15, 2010 | Wengreen et al. |
20100105627 | April 29, 2010 | Salama et al. |
20100144621 | June 10, 2010 | Kim et al. |
20100185184 | July 22, 2010 | Alessi et al. |
20100297209 | November 25, 2010 | Rohloff et al. |
20100298807 | November 25, 2010 | Jansen et al. |
20100298840 | November 25, 2010 | Schwartz |
20100331868 | December 30, 2010 | Bardy |
20100331878 | December 30, 2010 | Kleinwachter |
20110076317 | March 31, 2011 | Alessi et al. |
20110091527 | April 21, 2011 | Moonen et al. |
20110104111 | May 5, 2011 | Rohloff et al. |
20110152181 | June 23, 2011 | Alsina-Fernandez et al. |
20110152182 | June 23, 2011 | Alsina-Fernandez et al. |
20110160708 | June 30, 2011 | Berry et al. |
20110166554 | July 7, 2011 | Alessi et al. |
20110264077 | October 27, 2011 | Rohloff et al. |
20110306549 | December 15, 2011 | Tatarkiewicz et al. |
20120178687 | July 12, 2012 | Alessi et al. |
20120208755 | August 16, 2012 | Leung |
20120265232 | October 18, 2012 | Surbone |
20120303045 | November 29, 2012 | Cooper et al. |
20130030417 | January 31, 2013 | Alessi |
20130034210 | February 7, 2013 | Rohloff et al. |
20130052237 | February 28, 2013 | Eliaz et al. |
20130296661 | November 7, 2013 | Bornzin et al. |
20130324977 | December 5, 2013 | Vanderpool |
20140058409 | February 27, 2014 | Bratlie |
20140058425 | February 27, 2014 | Porat |
20140121741 | May 1, 2014 | Bennett et al. |
20140148837 | May 29, 2014 | Levitan |
20140163057 | June 12, 2014 | Patel et al. |
20140236162 | August 21, 2014 | Barongan |
20140257272 | September 11, 2014 | Clark, III et al. |
20140324067 | October 30, 2014 | Emken et al. |
20140378900 | December 25, 2014 | Alessi et al. |
20150111818 | April 23, 2015 | Alessi et al. |
20150057227 | February 26, 2015 | Leung |
20150133791 | May 14, 2015 | Sato et al. |
20150231062 | August 20, 2015 | Lautenbach et al. |
20150231256 | August 20, 2015 | Berry et al. |
20150297509 | October 22, 2015 | Schwarz |
20150359553 | December 17, 2015 | Harnisch |
20160022582 | January 28, 2016 | Alessi et al. |
20160030337 | February 4, 2016 | Kuzma et al. |
20160158577 | June 9, 2016 | Escarguel |
20160354115 | December 8, 2016 | Smith et al. |
20160354305 | December 8, 2016 | Alessi et al. |
20170056476 | March 2, 2017 | Rohloff et al. |
20170079906 | March 23, 2017 | Alessi et al. |
20170119854 | May 4, 2017 | Alessi et al. |
20170119855 | May 4, 2017 | Berry et al. |
20170181964 | June 29, 2017 | Lautenbach et al. |
20170252409 | September 7, 2017 | Leung |
20170273706 | September 28, 2017 | Mirza et al. |
20170319470 | November 9, 2017 | Eliaz et al. |
20170319662 | November 9, 2017 | Berry et al. |
20170348392 | December 7, 2017 | Rohloff et al. |
20170368145 | December 28, 2017 | Alessi et al. |
20180009871 | January 11, 2018 | Blackwell et al. |
20180185451 | July 5, 2018 | Young et al. |
20180193059 | July 12, 2018 | Bae et al. |
20180368875 | December 27, 2018 | Castillo |
0079405 | May 1983 | EP |
0254394 | January 1988 | EP |
0295411 | December 1988 | EP |
0368339 | May 1990 | EP |
0373867 | June 1990 | EP |
0431942 | June 1991 | EP |
0486959 | May 1992 | EP |
0521586 | January 1993 | EP |
0379147 | September 1994 | EP |
0627231 | December 1994 | EP |
0729747 | May 1997 | EP |
0771817 | May 1997 | EP |
0841359 | May 1998 | EP |
0767689 | June 1999 | EP |
1046399 | October 2000 | EP |
1084703 | March 2001 | EP |
1300129 | April 2003 | EP |
1300173 | April 2003 | EP |
1600187 | January 2009 | EP |
2133073 | December 2009 | EP |
2020990 | September 2010 | EP |
640907 | July 1928 | FR |
1049104 | November 1966 | GB |
1518683 | July 1978 | GB |
H02124814 | May 1990 | JP |
H07196479 | August 1995 | JP |
9241153 | September 1997 | JP |
11-100353 | April 1999 | JP |
2006/213727 | August 2006 | JP |
2010-200838 | September 2010 | JP |
9100160 | August 1992 | NL |
592113 | August 2012 | NZ |
200634060 | October 2006 | TW |
WO 1989/003678 | May 1989 | WO |
WO 1990/013285 | November 1990 | WO |
WO 1990/013361 | November 1990 | WO |
WO 1990/013780 | November 1990 | WO |
WO 1991/07160 | May 1991 | WO |
WO 1992/019241 | November 1992 | WO |
WO 1993/06819 | April 1993 | WO |
WO 1993/06821 | April 1993 | WO |
WO 1993/008832 | May 1993 | WO |
WO 1993/09763 | May 1993 | WO |
WO 1993/23083 | November 1993 | WO |
WO 1994/09743 | May 1994 | WO |
WO 1994/010982 | May 1994 | WO |
WO 1994/21262 | September 1994 | WO |
WO 1995/01167 | January 1995 | WO |
WO 1995/09006 | April 1995 | WO |
WO 1995/09007 | April 1995 | WO |
WO 1995/013799 | May 1995 | WO |
WO 1995/34285 | December 1995 | WO |
WO 1996/001134 | January 1996 | WO |
WO 1996/003116 | February 1996 | WO |
WO 1996/036317 | November 1996 | WO |
WO 1996/39142 | December 1996 | WO |
WO 1996/40049 | December 1996 | WO |
WO 1996/40139 | December 1996 | WO |
WO 1996/40355 | December 1996 | WO |
WO 1997/15289 | May 1997 | WO |
WO 1997/15296 | May 1997 | WO |
WO 1997/28181 | August 1997 | WO |
WO 1997/031943 | September 1997 | WO |
WO 1997/044039 | November 1997 | WO |
WO 1997/46204 | December 1997 | WO |
WO 1997/47339 | December 1997 | WO |
WO 1998/00152 | January 1998 | WO |
WO 1998/00157 | January 1998 | WO |
WO 1998/00158 | January 1998 | WO |
WO 1998/02169 | January 1998 | WO |
WO 1997/041837 | February 1998 | WO |
WO 1998/007412 | February 1998 | WO |
WO 98/013092 | April 1998 | WO |
WO 1998/16250 | April 1998 | WO |
WO 1998/17315 | April 1998 | WO |
WO 1998/20930 | May 1998 | WO |
WO 1998/27960 | July 1998 | WO |
WO 1998/027962 | July 1998 | WO |
WO 1998/27963 | July 1998 | WO |
WO 1998/030231 | July 1998 | WO |
WO 1998/32463 | July 1998 | WO |
WO 1998/42317 | October 1998 | WO |
WO 1998/47487 | October 1998 | WO |
WO 1998/51282 | November 1998 | WO |
WO 1999/03453 | January 1999 | WO |
WO 1999/04767 | February 1999 | WO |
WO 1999/004768 | February 1999 | WO |
WO 1999/012549 | March 1999 | WO |
WO 1999/16419 | April 1999 | WO |
WO 1999/025728 | May 1999 | WO |
WO 1999/29306 | June 1999 | WO |
WO 1999/033446 | July 1999 | WO |
WO 1999/33449 | July 1999 | WO |
WO 1999/39700 | August 1999 | WO |
WO 1999/040788 | August 1999 | WO |
WO 1999/044659 | September 1999 | WO |
WO 1999/062501 | December 1999 | WO |
WO 1999/064061 | December 1999 | WO |
WO 2000/013663 | March 2000 | WO |
WO 2000/029206 | May 2000 | WO |
WO 2000/038652 | July 2000 | WO |
WO 2000/040273 | July 2000 | WO |
WO 2000/041548 | July 2000 | WO |
WO 2000/045790 | August 2000 | WO |
WO 2000/054745 | September 2000 | WO |
WO 2000/059476 | October 2000 | WO |
WO 2000/066087 | November 2000 | WO |
WO 2000/066138 | November 2000 | WO |
WO 2000/067728 | November 2000 | WO |
WO 2001/019345 | March 2001 | WO |
WO 2001/028525 | April 2001 | WO |
WO 2001/043528 | June 2001 | WO |
WO 2001/051041 | July 2001 | WO |
WO 2001/78683 | October 2001 | WO |
WO 2002/028366 | April 2002 | WO |
WO 2002/036072 | May 2002 | WO |
WO 2002/043800 | June 2002 | WO |
WO 2002/045752 | June 2002 | WO |
WO 2002/47716 | June 2002 | WO |
WO 2002/067895 | September 2002 | WO |
WO 2002/069983 | September 2002 | WO |
WO 02/083216 | October 2002 | WO |
WO 2002/76344 | October 2002 | WO |
WO 2002/085428 | October 2002 | WO |
WO 2003/000230 | January 2003 | WO |
WO 2003/007981 | January 2003 | WO |
WO 2003/011892 | February 2003 | WO |
WO 2003/020245 | March 2003 | WO |
WO 2003/024357 | March 2003 | WO |
WO 2003/024503 | March 2003 | WO |
WO 2003/030923 | April 2003 | WO |
WO 2003/041684 | May 2003 | WO |
WO 2003/041757 | May 2003 | WO |
WO 2003/053400 | July 2003 | WO |
WO 2003/066585 | August 2003 | WO |
WO 2003/072113 | September 2003 | WO |
WO 2003/072133 | September 2003 | WO |
WO 2004/002565 | January 2004 | WO |
WO 2004/034975 | April 2004 | WO |
WO 2004/035754 | April 2004 | WO |
WO 2004/035762 | April 2004 | WO |
WO 2004/036186 | April 2004 | WO |
WO 2004/052336 | June 2004 | WO |
WO 2004/056338 | July 2004 | WO |
WO 2004/089335 | October 2004 | WO |
WO 2004/103342 | December 2004 | WO |
WO 2005/048930 | June 2005 | WO |
WO 2005/048952 | June 2005 | WO |
WO 2005/102293 | November 2005 | WO |
WO 2005/110425 | November 2005 | WO |
WO 2006/017772 | February 2006 | WO |
WO 2006/023526 | March 2006 | WO |
WO 2006/081279 | August 2006 | WO |
WO 2006/083761 | August 2006 | WO |
WO 2006/084139 | August 2006 | WO |
WO 2006/086727 | August 2006 | WO |
WO 2006/101815 | September 2006 | WO |
WO 2006/111169 | October 2006 | WO |
WO 2006/131730 | December 2006 | WO |
WO 2007/024700 | March 2007 | WO |
WO 2007/056681 | May 2007 | WO |
WO 2007/075534 | July 2007 | WO |
WO 2007/084460 | July 2007 | WO |
WO 2007/133778 | November 2007 | WO |
WO 2007/140416 | December 2007 | WO |
WO 2008/021133 | February 2008 | WO |
WO 2008/041245 | April 2008 | WO |
WO 2008/061355 | May 2008 | WO |
WO 2008/133908 | November 2008 | WO |
WO 2008/134425 | November 2008 | WO |
WO 2009/109927 | September 2009 | WO |
WO 2009/143285 | November 2009 | WO |
WO 2011/011697 | January 2011 | WO |
WO 2013/004983 | January 2013 | WO |
WO 2013/118109 | August 2013 | WO |
WO 2013/160347 | October 2013 | WO |
- “Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209211 (Dec. 1994).
- Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-Alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997).
- Adolf et al., “Antigenic structure of human interferon ω1α11 (Interferon all 1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987).
- Adolf et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991).
- Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990).
- Adolf et al., “Purification and characterization of natural human interferon ω1,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
- Adolf, “Human interferon omega-a review,” Mult. Sclr. 1:S44-47 (1995).
- Ahn et al., “A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning” Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116.
- Akers, et al., “Formulation Design and Development of Parenteral Suspensions,” Journal of Parenteral Science & Technology, 41(3): 88-96 (1987).
- Alonso et al. “Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres,” Pharmaceutical Research, 10(7): 945-953 (1993).
- Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
- Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
- Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
- ASTM International, AnnualBook of ASTM Standards, 8.02:208-211, 584-587 (1984).
- Aulitzky, “Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama,” Journal of Clinical Oncology 7(12):1875-1884 (1989).
- Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C,” Bioconjugate Chemistry 12(2):195-202 (2001).
- Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996).
- Bakhtiar et al, “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
- Balkwill,F., “Interferons,” Lancet 1(8646):1060-1063 (May 1989).
- Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
- Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419423 (Feb. 2001).
- Bell et al, “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995).
- Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983).
- Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995).
- Bodmeier and McGinity, “Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method,” International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988).
- Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994).
- Bolinger et al., “Recombinant interferon y for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992).
- Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
- Borden et al., “Second-generation interferons for cancer: Clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
- Boué et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-w1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000).
- Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
- Buckwold et. al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
- Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996).
- CAS Number: 56-81-5 (Nov. 16, 1984).
- Cha and Pitt, “A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules,” Journal of Controlled Release, 7: 69-78 (1988).
- Cha and Pitt, “The acceleration of degradation-controlled drug delivery from polyester microspheres,” Journal of Controlled Release, 8: 259-265 (1989).
- Chang et al., “Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996).
- Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967).
- Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
- Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983).
- Cohen et al., “Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres,” Pharmaceutical Research, 8(6): 713-720 (1991).
- Condino-Neto, “Interferon-y improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000).
- Conti, et al., “Use of polylactic acid for the preparation of microparticulate drug delivery systems,” Journal of Microencapsulation, 9(2): 153-166 (1992).
- Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002).
- Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
- Das et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm, 2(11):44-51 (1999).
- Dash et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998).
- Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ).
- Deacon et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
- Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994).
- Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose a-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
- Dorr et al., “Phase I-II trial of interferon-Alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988).
- Efendic et al., “Overview of incretin hormones,” Horm. Metab. Res., 36(11-12):742-746 (2004).
- Eissele et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994).
- Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-a for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000).
- Eng et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992).
- Eng et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990).
- Eppstein et al., “Biological activity of liposome-encapsulated murine interferon y is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985).
- Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993).
- Erowid,“Introduction to the Federal Controlled Substance Analog Act” 2001, 4 pages.
- Ertl et al., “Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines,” Vaccine 14(9):879-885.(1996).
- Fang et al., “The impact of baseline liver histology on virologic response to interferon a-2b±p ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
- Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993).
- Ferenci et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977).
- Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon a,” Lancet 356(9223):41 (Jul. 2000).
- Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase,” J. Medicinal Chem. 38(19):3829-3837 (1995).
- Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001).
- Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP),” Int'l J. Pharmaceutics 234(1-2): 121-128 (2002).
- Gao et al. “Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans,”Drug Metabolism and Disposition, vol. 40, No. 5, pp. 990-997 (2012).
- Gan To Kagaku Ryoho, “Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract).
- Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
- Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer,” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
- Georgios, et al. “Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers,” Advances in Therapy, Health Communications, Metuchen, NJ, US, vol. 32, No. 7, Jul. 10, 2015, pp. 650-661.
- Ghiglione et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia 27:599600 (1984).
- Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
- Glumetza Brochure 2009, 13 Pages.
- Goke et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993).
- Gonzales et al., “Randomized controlled trialincluding an initial 4-week ‘induction’ period during one year of high-dose interferon a-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975).
- Gonzalez, et al., “Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico,” Salud Publica Mex 55:462-468 (2013).
- Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon Alpha,” Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995).
- Grant et al., “Combination therapy with interferon-a plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439442 (Aug. 2000).
- Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992).
- Hageman, “The Role of Moisture in Protein Stability,” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988).
- Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972).
- Heathcote et al., “Peginterferon Alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23):1673-1680 (2000).
- Heim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
- Heinrich et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984).
- Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998).
- Hellstrand et al., “Histamine and the response to IFN-a in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
- Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
- Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010).
- Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993).
- Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953).
- Hodoshima et al., “Lipid nanoparticles for delivering antitumor drugs,” InterNational Journal of Pharmaceutics, 146(1):81-92 (1997).
- Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
- Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice” Cancer Res 59(16):4064-4068 (Aug. 1999).
- Hubel et al., “A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11 Suppl 5:S47S51 (Dec. 1997).
- Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
- Iacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer,” Am. J. Clin. Oncol. 18(1):27-31 (1995).
- IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993).
- INTERMUNE® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
- Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957).
- Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimentalparvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998).
- Jain et al., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000).
- Jalil and Nixon, “Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties,” Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990).
- Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994).
- Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” The Oncologist 12(9):11431150 (2007).
- Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
- Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996).
- Khalili et al., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000).
- Kildsig et al., “Theroretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970).
- Kirkwood et al., “Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group TrialEST 1684,” J. Clin. Oncol. 14(1):7-17 (1996).
- Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-y,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990).
- Knepp et al, “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996).
- Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human Alpha interferon at elevated temperatures,” Pharma. Res. 15(7):1090-1095 (1998).
- Knobler et al., “Systemic a-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984).
- Kovacevic et al., “Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant a-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
- Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-lb therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000).
- Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986).
- Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon- ω),” J. Interferon Res. 14:57-59 (1994).
- Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996).
- Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
- Lee and Timasheff, “The stabilization of proteins by sucrose,” J. Biological Chem., 256(14): 7193-7201 (Jul. 1981).
- Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).
- Lee, “Therapy of hepatitis C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
- Li et al. “Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010.
- Li, et al., “Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method,” Journal of Controlled Release, 37: 199-214 (1995).
- Lopez et al., “Mammalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
- Lublin et al., “Defining the Clinical course of multiple sclerosis: results of an International survey,” Neurology. 46:907-911 (1996).
- Lukaszewski et al., “Pegylated a interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000).
- Lund et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
- Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997).
- Maa and Hsu, “Liquid-liquid emulsification by static mixers for use in microencapsulation,” Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996).
- Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preClinical and Clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
- Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996).
- Malley et al., “Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
- Manning et al, “Stability of protein Pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989).
- Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965).
- Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
- Maulding, et al., “Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament,” Journal of Controlled Release, 3: 103-117 (1986).
- Mchutchison et al., “Interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998).
- Mehta, et al., “Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide),” Journal of Controlled Release, 41: 249-257 (1996).
- Meier et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
- Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-a plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000).
- Milella et al., “Neutralizing antibodies to recombinant a-interferon and response to therapy in chronic hepatitis C infection,” Liver 13(3):146-150 (Jun. 1993).
- Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972).
- Mojsov, “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992).
- Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953).
- Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001).
- Nauck et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998).
- Neumann et al., “Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998).
- Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-a-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
- Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005).
- Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Pharm. Sci. 13(4):393-401 (2001).
- Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
- Ortiz et al., “A differential scanning calorimetry study of the interaction of a-tocopherol with mixtures of phospholipids,”Biocim et Biophys Acta 898(2):214-222 (1987).
- Palmeri et al., “5-Fluorouracil and recombinant a-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327-330 (Oct. 1990).
- Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992).
- Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two year study,” Acta. Neurol. Scand. 100:283-289 (1999).
- Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis,” Neurology 43:662-667 (1993).
- Patzelt et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979).
- PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
- Peterson et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
- Peterson et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990).
- Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973).
- Plauth et al, “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
- Plauth et al, “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
- Pohl et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalianhomologues,” J. Biol. Chem., 273(16):9778-9784 (1998).
- Poynard et al., “Is an ‘a la carte’ combined interferon a 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211-218 (Jan. 2000).
- Poynard et al., “Randomized trial of interferon a 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998).
- Pratley et al., “Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors,” Rev. Diabet. Stud., 5(2):73-94 (2008).
- Quesada et al., “Interferons in Hematological Malignancies”, eds. Baron et al., U. Tex. 487-495 (1987).
- Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011).
- Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997).
- Rajkumar et al., “Phase I evaluation of radiation combined with recombinant interferon Alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
- Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010).
- Roberts et al., “The Evolution of the Type I Interferons 1,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998).
- Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
- Roff et al., “Handbook of Common Polymers”, Cleveland Rubber Co. 72 pages (1971).
- Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957).
- Rohloff et al., “DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
- Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4):554-558 (1989).
- Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):6054-61 (Dec. 2007).
- Roth et al., “High Dose Etretinate and Interferon-Alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999).
- Sah, et al., “A novel method of preparing PLGA microcapsules utilizing methylethyl ketone,” Pharmaceutical Research, 13(3): 360-367 (1996).
- Sato, et al., “Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques,” Pharmaceutical Research, 5(1): 21-30 (1988).
- Schepis et al. “Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection,” Hepatology, 33(2); 333-338 (2001).
- Schepp et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994).
- Schering Corp., Intone® A for Injection, 6 pages (2001).
- Schering Corp., PEG-IntronTM (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
- Schmalfub et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997).
- Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
- Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000).
- Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000).
- Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004).
- Simon et al., “A longitudinal study of Ti hypointense lesions in relapsing MS: MSCRG trial of interferon 131a,” Neurology 55(2):185-192 (Jul. 2000).
- Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
- Sparks et al., “Lipoprotein Alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998).
- Sulkowski et al., “Peginterferon-a-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002).
- Szayna, et al., “Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats,” Endocrinology, 141(6): 1936-1941 (2000).
- Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon Alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001).
- Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9): 3748-56 (Sep. 2005).
- Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000).
- Taylor et al. “Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes,” Horm. Metab. Res. 37: 627-632 (2005).
- Thomasin, et al., “A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation,” Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996).
- Thompson et al., “Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone,” Journal of Controlled Release 43(1):9-22 (1997).
- Tong et al., “Prediction of response during interferon a 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997).
- Touza Rey et al., “The Clinical response to interferon-y in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000).
- Tracy et al., “Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro.” Biomaterials. 20(11:): 1057-1062 (1999).
- Trudeau et al., “A phase I study of recombinant human interferon Alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer,” Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
- Tseng et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993).
- Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997).
- Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006).
- van Santbrink and Fauser, “Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens,” J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997).
- Vokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
- Vrabec, “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
- Wang et al, “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
- Wang et al., “Preferential interaction of a-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000).
- Wang et al., “Ripple phases induced by a-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000).
- Wang et al., “The distribution of a-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000).
- Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011).
- Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999).
- Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with a interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
- Yu et al. “Glucagon-like peptide 1 based therapy for type 2 diabetes,” World Journal of Pediatrics vol. 4, No. 1, Feb. 1, 2008, pp. 8-13.
- Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996).
- Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-0160 (Apr. 1989).
- Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998).
- Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon a on viral turnover,” Hepatology 28(1):245-252 (Jul. 1998).
- Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl. J. Med. 343(23):1666-1672 (2000).
- Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997).
- Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996).
- Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998).
- Ziesche et al., “A preliminary study of long-term treatment with interferon y-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999).
Patent History
Patent number: D912249
Type: Grant
Filed: Jul 24, 2019
Date of Patent: Mar 2, 2021
Assignee: INTARCIA THERAPEUTICS, INC. (Boston, MA)
Inventors: Jay S. Smith (Wellesley Hills, MA), Michael R. Cole (Stratham, NH)
Primary Examiner: Wan Laymon
Application Number: 29/699,323
Type: Grant
Filed: Jul 24, 2019
Date of Patent: Mar 2, 2021
Assignee: INTARCIA THERAPEUTICS, INC. (Boston, MA)
Inventors: Jay S. Smith (Wellesley Hills, MA), Michael R. Cole (Stratham, NH)
Primary Examiner: Wan Laymon
Application Number: 29/699,323
Classifications
Current U.S. Class:
Clamp Or Forceps (28) (D24/143)